2023
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study
Schmid P, Lipatov O, Im S, Goncalves A, Muñoz-Couselo E, Lee K, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Mejia J, Zhou X, Haiderali A, Nguyen A, Cortes J, Winer E. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study. European Journal Of Cancer 2023, 195: 113393. PMID: 37976633, DOI: 10.1016/j.ejca.2023.113393.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerCombined positive scoreMetastatic triple-negative breast cancerPD-L1 combined positive scoreHealth-related qualityBreast cancerQLQ-C30 functional scalesTumor PD-L1 expressionGHS/QoLNausea/vomitingPD-L1 expressionStart of treatmentHRQoL resultsEligible patientsHRQoL analysisOverall survivalSystemic therapyClinical outcomesFunctional scalesPhysician's choicePatientsChemotherapyFirst onsetCountry guidelinesMedian TTDImpact of Head and Neck Cancer Treatment on CD4 T Cell Decline and Recovery in People with HIV
Hicks D, Salahuddin S, Wu M, Perez-Irizarry J, Emu B, Park H. Impact of Head and Neck Cancer Treatment on CD4 T Cell Decline and Recovery in People with HIV. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e588. DOI: 10.1016/j.ijrobp.2023.06.1934.Peer-Reviewed Original ResearchCells/mm3CD4 countPercentage of baselineMann-Whitney testCD4 T-cell declineMedian baseline CD4 countMedian nadir CD4 countCancer treatmentBaseline CD4 countCancer treatment initiationMedian baseline CD4Treatment-related immunosuppressionNadir CD4 countMajority of patientsRetrospective chart reviewTime of diagnosisStart of treatmentT-cell declineNeck cancer treatmentMATERIAL/METHODSNonparametric Mann-Whitney testBaseline CD4Immunologic declineMedian CD4Antiretroviral therapyRandomized trial evaluating an mHealth intervention for the early community-based detection and follow-up of cutaneous leishmaniasis in rural Colombia
Castillo M, Alexander N, Rubiano L, Rojas C, Navarro A, Rincon D, Bernal L, Lerma Y, Saravia N, Aronoff-Spencer E. Randomized trial evaluating an mHealth intervention for the early community-based detection and follow-up of cutaneous leishmaniasis in rural Colombia. PLOS Neglected Tropical Diseases 2023, 17: e0011180. PMID: 36972285, PMCID: PMC10079216, DOI: 10.1371/journal.pntd.0011180.Peer-Reviewed Original ResearchConceptsEffectiveness of treatmentIntervention armWeek 26Therapeutic responseCutaneous leishmaniasisHealth systemSerious adverse eventsEnd of treatmentStart of treatmentCutaneous leishmaniasis treatmentProportion of participantsMobile health strategiesPublic health systemCommunity-based detectionTreatment of CLPrimary endpointAdverse eventsMore patientsClinical managementControl armImproved careMedical attentionNational guidelinesParallel armsHealth strategiesDelay in the diagnosis and treatment of tuberculosis in prisons in Mato Grosso do Sul, Brazil
Ribeiro C, da Silva Santos A, Tshua D, de Oliveira R, Lemos E, Bourdillon P, Laranjeira A, Gonçalves C, Andrews J, Ko A, Croda J. Delay in the diagnosis and treatment of tuberculosis in prisons in Mato Grosso do Sul, Brazil. Revista Da Sociedade Brasileira De Medicina Tropical 2023, 56: e0015-2023. PMID: 37493729, PMCID: PMC10367220, DOI: 10.1590/0037-8682-0015-2023.Peer-Reviewed Original ResearchConceptsSymptom onsetFirst symptomsLargest male prisonPrison medical recordsTB case dataRetrospective cohort studyPulmonary TB casesYear of diagnosisStart of treatmentTreatment of TBTreatment of tuberculosisNumber of symptomsAverage timePercentage of cureProvider delayTB casesCohort studyTreatment initiationHIV statusSmoking statusTuberculosis casesTB transmissionFirst consultationPatient delayMedical records
2022
A Comparison of Patient- and Clinician-Reported Acute Toxic Effects During Radiation Therapy for Primary Breast Cancer
Lapen K, King C, Braunstein L, Khan A, Kamrava M, Gillespie E, Cook K. A Comparison of Patient- and Clinician-Reported Acute Toxic Effects During Radiation Therapy for Primary Breast Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: 301-309. PMID: 35675851, PMCID: PMC10281649, DOI: 10.1016/j.ijrobp.2022.05.041.Peer-Reviewed Original ResearchConceptsPrimary breast cancerRadiation therapyAcute toxic effectsClinician assessmentBreast cancerPatients warrants further investigationTreatment-related toxic effectsToxic effectsPatient-clinician pairsSymptom burden scoresCommon Terminology CriteriaComparison of patientsStart of treatmentBreast radiation therapyWarrants further investigationTerminology CriteriaAdverse eventsSymptom burdenOutcomes versionPatients' qualityBurden scoreProspective studyUnique patientsLow-severity symptomsPatient response
2021
Detecting change in psychiatric functioning in clinical trials for cocaine use disorder: sensitivity of the Addiction Severity Index and Brief Symptom Inventory
Kiluk BD, Roos CR, Aslan M, Gueorguieva R, Nich C, Babuscio TA, Carroll KM. Detecting change in psychiatric functioning in clinical trials for cocaine use disorder: sensitivity of the Addiction Severity Index and Brief Symptom Inventory. Drug And Alcohol Dependence 2021, 228: 109070. PMID: 34600247, PMCID: PMC8595796, DOI: 10.1016/j.drugalcdep.2021.109070.Peer-Reviewed Original ResearchConceptsAddiction Severity IndexGlobal Severity IndexPsychiatric composite scoreClinical trialsCocaine useCocaine use disorderPsychiatric functioningBrief Symptom InventorySeverity IndexUse disordersASI psychiatric composite scoreSymptom InventoryEffect sizeStart of treatmentComposite scoreClinical trial participantsWeek 12Functional outcomeTreatment periodTrial participantsPsychiatric problemsDrug usePotential functional benefitsMedium effect sizeSubstance users
2020
Abnormal Liver Function Tests in Patients With COVID‐19: Relevance and Potential Pathogenesis
Bertolini A, van de Peppel I, Bodewes FAJA, Moshage H, Fantin A, Farinati F, Fiorotto R, Jonker JW, Strazzabosco M, Verkade HJ, Peserico G. Abnormal Liver Function Tests in Patients With COVID‐19: Relevance and Potential Pathogenesis. Hepatology 2020, 72: 1864-1872. PMID: 32702162, PMCID: PMC7404414, DOI: 10.1002/hep.31480.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAbnormal liver function testsLiver function testsCOVID-19 patientsAspartate aminotransferaseFunction testsHospitalized coronavirus disease 2019 (COVID-19) patientsSevere COVID-19 diseaseCoronavirus disease 2019 (COVID-19) patientsElevated liver function testsPre-existing liver diseaseDrug-induced liver injuryCOVID-19Hyper-inflammatory statusAlanine aminotransferase levelsLopinavir/ritonavirOvert liver failureStart of treatmentUse of acetaminophenCause of deathPlasma aspartate aminotransferaseUpper reference limitSARS-CoV-2COVID-19 diseaseAlkaline phosphataseALT elevationPatient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC.
de Marinis F, Giaccone G, Herbst R, Oprean C, Szczesna A, Boukovinas I, Bonomi L, Kim Y, Summers Y, Kurata T, Komatsubara K, Chen M, Deng Y, Kuriki H, Mocci S, Phan S, Jassem J, Spigel D. Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC. Journal Of Clinical Oncology 2020, 38: 9594-9594. DOI: 10.1200/jco.2020.38.15_suppl.9594.Peer-Reviewed Original ResearchPatient-reported outcomesGlobal health statusLung cancer-related symptomsLung cancer symptomsCancer-related symptomsChest painWk 48Metastatic NSCLCSymptom burdenPhysical functionCancer symptomsLife Questionnaire Core 30Carboplatin AUC 6Overall clinical benefitStart of treatmentCompletion ratesAUC 5AUC 6Gemcitabine 1250Meaningful worseningNausea/OS benefitQLQ-LC13Primary endpointPD-L1Effectiveness of enhanced cognitive behavior therapy for bulimia nervosa in Japan: a randomized controlled trial protocol
Ohara C, Sekiguchi A, Takakura S, Endo Y, Tamura N, Kikuchi H, Maruo K, Sugawara N, Hatano K, Kawanishi H, Funaba M, Sugawara A, Nohara N, Kawai K, Fukudo S, Sudo N, Cooper Z, Yoshiuchi K, Ando T. Effectiveness of enhanced cognitive behavior therapy for bulimia nervosa in Japan: a randomized controlled trial protocol. BioPsychoSocial Medicine 2020, 14: 2. PMID: 32123540, PMCID: PMC7041176, DOI: 10.1186/s13030-020-0174-z.Peer-Reviewed Original ResearchCognitive behavior therapyBody mass indexStart of treatmentBulimia nervosaBehavior therapyEffectiveness of CBTTreatment of BNDiagnosis of BNFifth Edition diagnosisWeeks of treatmentEnd of treatmentYears of ageDSM-5 criteriaSecondary outcomesMulticenter RCTPrimary outcomeMass indexFirst RCTRoutine treatmentTAU groupTrial protocolAdult outpatientsEdition diagnosisHigh prevalenceIntervention sites
2019
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma
Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Bartlett C, Koehler M, Winer EP, Burstein HJ. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Annals Of Oncology 2019, 30: 1514-1520. PMID: 31250880, DOI: 10.1093/annonc/mdz198.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalEstradiolFeasibility StudiesFemaleFulvestrantHumansMiddle AgedNeoplasm InvasivenessNeoplasm StagingPiperazinesProtein Kinase InhibitorsPyridinesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneConceptsEarly breast cancerEndocrine therapyAdjuvant palbociclibBreast cancerHormone receptor-positive/HER2-negative metastatic breast cancerHER2-negative metastatic breast cancerPhase II feasibility studyProlong progression-free survivalRandomized phase III trialAdjuvant endocrine therapyPrimary end pointStage III diseasePhase II trialPhase III trialsProgression-free survivalMetastatic breast cancerYears of therapyStart of treatmentInvasive breast carcinomaEligible patientsFebrile neutropeniaPrior chemotherapyWeeks on/1II trialCumulative incidence
2018
Long-term Quality of Life in Survivors of Brain Metastases: A Roller Coaster of Perspective
Reddy NK, Brown FC, Fogarasi MC, Yu JB, Hess J, Chiang VS. Long-term Quality of Life in Survivors of Brain Metastases: A Roller Coaster of Perspective. Cureus 2018, 10: e2358. PMID: 29805927, PMCID: PMC5963947, DOI: 10.7759/cureus.2358.Peer-Reviewed Original Research
2016
Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. The Journal Of Clinical Psychiatry 2016, 77: e605-11. PMID: 27249090, DOI: 10.4088/jcp.14r09758.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsYale-Brown Obsessive Compulsive ScalePlacebo-controlled trialSerotonin reuptake inhibitorsTreatment of adultsObsessive-compulsive disorderSSRI responseSSRI treatmentReuptake inhibitorsSymptom improvementEfficacy of SSRIsTrials of SSRIsFirst-line pharmacologic treatmentCochrane Central RegisterStart of treatmentMajor depressive disorderEffect of doseObsessive Compulsive ScaleSSRI actionCentral RegisterPharmacologic treatmentPrimary outcomeControlled TrialsSSRI trialDepressive disorderMortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study
May MT, Vehreschild JJ, Trickey A, Obel N, Reiss P, Bonnet F, Mary-Krause M, Samji H, Cavassini M, Gill MJ, Shepherd LC, Crane HM, Monforte A, Burkholder GA, Johnson MM, Sobrino-Vegas P, Domingo P, Zangerle R, Justice AC, Sterling TR, Miró JM, Sterne JAC, Collaboration F, Boulle A, Stephan C, Miro J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Fätkenheuer G, Gill J, Guest J, Haerry D, Hogg R, Justice A, Shepherd L, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A. Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clinical Infectious Diseases 2016, 62: 1571-1577. PMID: 27025828, PMCID: PMC4885653, DOI: 10.1093/cid/ciw183.Peer-Reviewed Original ResearchConceptsStart of ARTMortality rate ratiosCombination antiretroviral therapyAntiretroviral therapyMortality of patientsCD4 countMortality rateLow baseline CD4 countYears of ARTBaseline CD4 countHigher baseline CD4Collaborative Cohort StudyStart of treatmentNorth American cohortStrong inverse associationLong-term survivalShort-term survivalBaseline CD4CD4 groupCohort studyInverse associationPatientsAmerican cohortYears durationMortality
2015
Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT.
Alagappan M, Pollom E, von Eyben R, Kunz P, Fisher G, Ford J, Poultsides G, Visser B, Norton J, Kamaya A, Columbo L, Koong A, Chang D. Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT. Journal Of Clinical Oncology 2015, 33: 433-433. DOI: 10.1200/jco.2015.33.3_suppl.433.Peer-Reviewed Original ResearchUnresectable pancreatic adenocarcinomaStereotactic body radiotherapyHigh NL ratioPrior radiation therapyOverall survivalBlood cell countStart of treatmentPancreatic adenocarcinomaTumor marker valuesNL ratioResectable diseaseEntire cohortCA 19Univariate analysisRadiation therapyCell countWhite blood cell countTumor marker CA 19Marker valuesLab valuesBorderline resectable diseasePre-treatment CEAMedian overall survivalAbsolute lymphocyte countAbsolute neutrophil count
2014
High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People
Kranz GS, Wadsak W, Kaufmann U, Savli M, Baldinger P, Gryglewski G, Haeusler D, Spies M, Mitterhauser M, Kasper S, Lanzenberger R. High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People. Biological Psychiatry 2014, 78: 525-533. PMID: 25497691, PMCID: PMC4585531, DOI: 10.1016/j.biopsych.2014.09.010.Peer-Reviewed Original ResearchConceptsSerotonin reuptake transporterSERT bindingFemale transsexualsStart of treatmentSteroid hormone treatmentNew treatment modalitiesTreatment of depressionMedian raphe nucleusHormone plasma levelsTreatment-induced increaseMid-cingulate cortexPositron emission tomographyMechanism of actionTreatment startSerotonergic transmissionEstradiol levelsRaphe nucleusEstrogen treatmentReuptake transporterTreatment modalitiesAndrogen treatmentEpidemiologic findingsPlasma levelsSex hormonesSERT expression
2011
Changes in intracortical microporosities induced by pharmaceutical treatment of osteoporosis as detected by high resolution micro-CT
Tommasini SM, Trinward A, Acerbo AS, De Carlo F, Miller LM, Judex S. Changes in intracortical microporosities induced by pharmaceutical treatment of osteoporosis as detected by high resolution micro-CT. Bone 2011, 50: 596-604. PMID: 22226688, PMCID: PMC3278519, DOI: 10.1016/j.bone.2011.12.012.Peer-Reviewed Original ResearchConceptsAge-matched controlsUntreated OVXEstrogen withdrawalSix-month-old female SpragueDifferent osteoporosis treatmentsUntreated OVX ratsStart of treatmentEndosteal regionOsteocyte lacunar sizeEffect of treatmentOVX ratsOsteoporosis treatmentFemale SpraguePTH treatmentDawley ratsCurrent treatmentNumber of lacunaeMedial cortexOsteocyte lacunaePharmaceutical treatmentOVXMedial quadrantAlendronateBone strengthFemoral diaphysisProposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types
Loi S, Symmans WF, Bartlett J, Fumagalli D, Veer L, Forbes JF, Bedard P, Denkert C, Zujewski J, Viale G, Pusztai L, Esserman LJ, Leyland-Jones BR. Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. The Lancet Oncology 2011, 12: 1162-1168. PMID: 21684810, DOI: 10.1016/s1470-2045(11)70117-6.Peer-Reviewed Original ResearchConceptsNorth American Breast Cancer GroupBreast International GroupClinical trialsBiopsy procedureNeoadjuvant breast cancer trialsNeoadjuvant clinical trialsBreast cancer clinical trialsBreast cancer groupBreast cancer trialsStart of treatmentCancer clinical trialsNational Cancer InstituteNeoadjuvant trialsDefinitive surgeryNeoadjuvant treatmentCancer groupStudy protocolCancer trialsBreast cancerCancer InstituteUniform collectionTumor tissueBlood collectionTrialsSpecimen types
2009
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies
Sterne J, May M, Costagliola D, de Wolf F, Phillips A, Harris R, Funk M, Geskus R, Gill J, Dabis F, Miró J, Justice A, Ledergerber B, Fätkenheuer G, Hogg R, Monforte A, Saag M, Smith C, Staszewski S, Egger M, Cole S. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. The Lancet 2009, 373: 1352-1363. PMID: 19361855, PMCID: PMC2670965, DOI: 10.1016/s0140-6736(09)60612-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesDisease ProgressionDrug Administration ScheduleEuropeFemaleHIV InfectionsHIV-1HumansKaplan-Meier EstimateMaleMiddle AgedNorth AmericaPatient SelectionPractice Guidelines as TopicProportional Hazards ModelsSensitivity and SpecificityTime FactorsTreatment OutcomeConceptsHIV-1-infected patientsCombination antiretroviral therapyCD4 cell countAntiretroviral therapyCombination therapyCohort studyCell countCD4 cell count rangeCD4 cell count thresholdAntiretroviral-naive patientsProspective cohort studyHIV Cohort StudyRates of AIDSStart of treatmentHigh mortality rateAbsence of treatmentTiming of initiationDeath eventsCell count thresholdTherapy groupImmediate initiationPatientsMortality rateTherapyAIDS
2002
Steroids for acute spinal cord injury
Bracken M. Steroids for acute spinal cord injury. 2002, cd001046. PMID: 12137616, DOI: 10.1002/14651858.cd001046.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute spinal cord injurySpinal cord injuryHours of injuryCord injuryMethylprednisolone therapySteroid treatmentPharmacological therapyRandomized trialsRecent trialsNational Acute Spinal Cord Injury StudyAcute Spinal Cord Injury StudyHigh-dose methylprednisolone steroid therapySpinal Cord Injury StudyMotor neurologic functionOnly pharmacological therapyNorth American trialsLumbar disc diseaseStart of treatmentMethylprednisolone sodium succinateCochrane Injuries GroupYears post injurySteroid therapyMaintenance infusionDose regimenInjury group
1999
Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease
Hohol M, Olek M, Orav E, Stazzone L, Hafler D, Khoury S, Dawson D, Weiner H. Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease. Multiple Sclerosis Journal 1999, 5: 403-409. PMID: 10618696, DOI: 10.1177/135245859900500i606.Peer-Reviewed Original ResearchConceptsProgressive multiple sclerosisDuration of progressionMultiple sclerosisProgressive diseaseSecondary progressive multiple sclerosisDuration of MSPrimary progressive patientsProgressive MS patientsPositive clinical responseOpen-label fashionClinical outcome measuresStart of treatmentOnset of diseaseMethylprednisolone therapySecondary progressiveImmunomodulatory treatmentImmunosuppressive therapyProgressive patientsClinical responsePatient characteristicsMS patientsImmunosuppressive agentsAutoimmune diseasesLabel fashionEDSS change
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply